Bicara Therapeutics Inc.
BCAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023658
In the last 90 days, Bicara Therapeutics Inc. insiders filed 0 open-market purchases and 7 sales; 171 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Bicara Therapeutics Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +14 vs. Q1 2025
- Shares held
- 51.2M
- +2.56M (+5.3%) vs. Q1 2025
- Total value
- $475.3M
- −$158.6M (−25.0%) vs. Q1 2025
- New holders
- 33
- 43 more added
- Sold out
- 19
- 16 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 171 | $2.07B |
| Q1 2026 | 145 | $1.35B |
| Q4 2025 | 140 | $960.7M |
| Q3 2025 | 114 | $792.5M |
| Q2 2025 | 106 | $475.3M |
| Q1 2025 | 93 | $633.9M |
| Q4 2024 | 84 | $813.6M |
| Q3 2024 | 69 | $927.6M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Bicara Therapeutics Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 2,538,404 | $23.6M | 0.00% | −1,073,169−29.7% | Reduced |
| TPG GP A, LLC | 3,010,425 | $28.0M | 1.49% | 00.0% | Unchanged |
| Red Tree Management, LLC | 3,170,509 | $29.5M | 40.18% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 5,000,000 | $46.5M | 2.45% | +2,231,025+80.6% | Added |
| Siren, L.L.C. | 5,216,969 | $48.5M | 2.51% | +1,949,886+59.7% | Added |
| Ra Capital Management, L.P. | 6,955,993 | $64.6M | 1.09% | 00.0% | Unchanged |
| Braidwell LP | 0 | $0 | 0.00% | −2,162,803−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −1,394,676−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −1,343,754−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −1,182,900−100.0% | Sold out |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −833,333−100.0% | Sold out |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −784,170−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −298,301−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −47,078−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −30,601−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −19,034−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −13,669−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −12,163−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −9,456−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −163−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −154−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| Rothschild Investment LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |